A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01)

A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01)

Abstract Background Although surgery is the definitive curative treatment for biliary tract cancer (BTC), outcomes after surgery alone have not been satisfactory. Adjuvant therapy with S-1 may improve survival in patients with BTC. This study examined the safety and efficacy of 1 year adjuvant S-1 t...

Full description

Bibliographic Details
Main Authors: Osamu Itano, Yusuke Takemura, Norihiro Kishida, Eiji Tamagawa, Hiroharu Shinozaki, Ken Ikeda, Hidejiro Urakami, Shigenori Ei, Shigeo Hayatsu, Keiichi Suzuki, Tadayuki Sakuragawa, Masatsugu Ishii, Masaya Shito, Koichi Aiura, Hiroto Fujisaki, Kiminori Takano, Junichi Matsui, Takuya Minagawa, Masahiro Shinoda, Minoru Kitago, Yuta Abe, Hiroshi Yagi, Go Oshima, Shutaro Hori, Yuko Kitagawa
Format: Article
Language:English
Published: BMC 2020-07-01
Series:BMC Cancer
Subjects:
Biliary tract cancer
Adjuvant chemotherapy
1-year administration of S-1
Feasibility study
Online Access:http://link.springer.com/article/10.1186/s12885-020-07185-6

Internet

http://link.springer.com/article/10.1186/s12885-020-07185-6

Similar Items